Genistein Exacerbation of Asthma in Mice

金雀异黄素加重小鼠哮喘

基本信息

  • 批准号:
    6858807
  • 负责人:
  • 金额:
    $ 14.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-05-02 至 2008-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Genistein (GEN), a soy isoflavone, has been suggested to mediate its biological function mainly as an endocrine disruptor instead of a tyrosine kinase inhibitor in vivo. Despite the hypothesized beneficial effects of GEN, there are concerns about the long-term effects of this compound on human health, especially that of infants and young children. The recent epidemiological findings indicate that there is an increase in the use of asthma or allergy drugs in young adults who have been fed soy formula during infancy as compared to those who have been fed cow milk formula. One important mechanism for development of asthma is that allergens repeatedly stimulate T helper (Th) 2-polarized T-cell immunity in local airway tissue. Our studies have provided evidence that the developing immune system, especially the function of T cells, was altered following oral exposure to GEN at physiologically relevant concentrations in experimental animals. It is hypothesized that developmental exposure to GEN modulates the chromatin structure of Th2 cytokine genes (e.g., IL-4 and IL-13) and, thus, leads to an increase in the hypersensitivity responses to respiratory allergen trimellitic anhydride (TMA) in adult life. To test this hypothesis, two specific aims will be pursued: (1) To determine if developmental exposure to GEN leads to an enhancement in hypersensitivity responses to respiratory allergen TMA in adult life; (2) To determine if developmental exposure to GEN leads to DNA demethylation and chromosome remodeling of Th2 cytokine genes such as IL-4 and IL-13. Results of this investigation will provide a rational basis for understanding the health implications associated with the consumption of this compound. By identifying possible cytokines that are important at increasing risks, by looking at vulnerable periods in life, and by identifying environmental factors which through different mechanisms may be driving the immunological processes (amongst others) that lead to asthma, we will gain a better insight with which to make informed decisions regarding intervention studies.
描述(由申请人提供):金雀异黄酮(GEN)是一种大豆异黄酮,已被认为主要作为内分泌干扰物而不是体内酪氨酸激酶抑制剂来介导其生物功能。尽管假设 GEN 具有有益作用,但人们仍然担心这种化合物对人类健康,尤其是婴儿和幼儿的长期影响。最近的流行病学研究结果表明,与喂养牛奶配方奶粉的年轻人相比,在婴儿期喂养大豆配方奶粉的年轻人中使用哮喘或过敏药物的情况有所增加。 哮喘发生的一个重要机制是过敏原反复刺激局部气道组织中的 T 辅助细胞 (Th) 2 极化 T 细胞免疫。我们的研究提供的证据表明,实验动物口服暴露于生理相关浓度的 GEN 后,发育中的免疫系统,尤其是 T 细胞的功能发生了改变。据推测,发育时期暴露于 GEN 会调节 Th2 细胞因子基因(例如 IL-4 和 IL-13)的染色质结构,从而导致成年后对呼吸道过敏原偏苯三酸酐 (TMA) 的超敏反应增加。为了检验这一假设,我们将追求两个具体目标:(1)确定发育时期接触 GEN 是否会导致成年后对呼吸道过敏原 TMA 的超敏反应增强; (2) 确定发育阶段暴露于 GEN 是否会导致 Th2 细胞因子基因(例如 IL-4 和 IL-13)的 DNA 去甲基化和染色体重塑。这项调查的结果将为了解与食用该化合物相关的健康影响提供合理的基础。通过识别可能对增加风险很重要的细胞因子,通过观察生命中的脆弱时期,并通过识别通过不同机制可能驱动导致哮喘的免疫过程(其中包括)的环境因素,我们将获得更好的洞察力,从而在干预研究方面做出明智的决定。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
In utero exposure to genistein decreased intranasal house dust mite-induced respiratory allergy in middle-aged male B6C3F1 offspring.
  • DOI:
    10.1016/j.toxlet.2020.07.013
  • 发表时间:
    2020-10-15
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Guo TL;Lefever DE;Nagy T;Meng AH
  • 通讯作者:
    Meng AH
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TAI L GUO其他文献

TAI L GUO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TAI L GUO', 18)}}的其他基金

Engineering probiotics to biosynthesize natural substances for microbiome-brain research
工程益生菌生物合成天然物质用于微生物组脑研究
  • 批准号:
    9332039
  • 财政年份:
    2017
  • 资助金额:
    $ 14.25万
  • 项目类别:
Exacerbation of type 1 diabetes in mice by bisphenol A and genistein
双酚 A 和染料木黄酮加剧小鼠 1 型糖尿病
  • 批准号:
    8770595
  • 财政年份:
    2014
  • 资助金额:
    $ 14.25万
  • 项目类别:
Genistein Exacerbation of Asthma in Mice
金雀异黄素加重小鼠哮喘
  • 批准号:
    6745089
  • 财政年份:
    2003
  • 资助金额:
    $ 14.25万
  • 项目类别:
Genistein Exacerbation of Asthma in Mice
金雀异黄素加重小鼠哮喘
  • 批准号:
    6646817
  • 财政年份:
    2003
  • 资助金额:
    $ 14.25万
  • 项目类别:

相似海外基金

Innate immune regulation of lung inflammation through mitochondrial dynamics
通过线粒体动力学调节肺部炎症的先天免疫
  • 批准号:
    10659953
  • 财政年份:
    2023
  • 资助金额:
    $ 14.25万
  • 项目类别:
Early life exposure to metal mixtures: impacts on asthma and lungdevelopment
生命早期接触金属混合物:对哮喘和肺部发育的影响
  • 批准号:
    10678307
  • 财政年份:
    2023
  • 资助金额:
    $ 14.25万
  • 项目类别:
Lung resident Treg suppression of Th2 resident memory T cells in allergic asthma
过敏性哮喘中肺常驻 Treg 对 Th2 常驻记忆 T 细胞的抑制
  • 批准号:
    10664599
  • 财政年份:
    2023
  • 资助金额:
    $ 14.25万
  • 项目类别:
Data Management and Bioinformatics
数据管理和生物信息学
  • 批准号:
    10633367
  • 财政年份:
    2023
  • 资助金额:
    $ 14.25万
  • 项目类别:
ECHO Renewal for the INSPIRE Study Cohort
INSPIRE 研究队列的 ECHO 更新
  • 批准号:
    10745075
  • 财政年份:
    2023
  • 资助金额:
    $ 14.25万
  • 项目类别:
EXposomic Profiling in Airway disease to uNravel Determinants of disease in Asthma (EXPAND-Asthma) Center
气道疾病暴露组分析以解开哮喘疾病的决定因素 (EXPAND-Asthma) 中心
  • 批准号:
    10744673
  • 财政年份:
    2023
  • 资助金额:
    $ 14.25万
  • 项目类别:
Early Life Pulmonary Infection, Microbiome and Trained Innate Immunity
生命早期肺部感染、微生物组和经过训练的先天免疫
  • 批准号:
    10677304
  • 财政年份:
    2023
  • 资助金额:
    $ 14.25万
  • 项目类别:
Regulation of tissue-resident helper type 2 T cells by fatty acid transport protein 4 (FATP4)
脂肪酸转运蛋白 4 (FATP4) 对组织驻留辅助型 2 T 细胞的调节
  • 批准号:
    10677098
  • 财政年份:
    2023
  • 资助金额:
    $ 14.25万
  • 项目类别:
Optimizing function-selective ERK1/2 inhibitors for reducing AP-1-mediated airway pathology in asthma.
优化功能选择性 ERK1/2 抑制剂以减少 AP-1 介导的哮喘气道病理。
  • 批准号:
    10666887
  • 财政年份:
    2023
  • 资助金额:
    $ 14.25万
  • 项目类别:
Cohort Administration and Biorepository Core
队列管理和生物样本库核心
  • 批准号:
    10633366
  • 财政年份:
    2023
  • 资助金额:
    $ 14.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了